Ameriflex Group Inc. Sells 1,640 Shares of Gilead Sciences, Inc. $GILD

Ameriflex Group Inc. cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 56.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,288 shares of the biopharmaceutical company’s stock after selling 1,640 shares during the period. Ameriflex Group Inc.’s holdings in Gilead Sciences were worth $139,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. Southland Equity Partners LLC grew its holdings in shares of Gilead Sciences by 2.9% in the second quarter. Southland Equity Partners LLC now owns 3,285 shares of the biopharmaceutical company’s stock valued at $364,000 after acquiring an additional 92 shares in the last quarter. Twelve Points Wealth Management LLC grew its holdings in shares of Gilead Sciences by 1.5% in the second quarter. Twelve Points Wealth Management LLC now owns 6,499 shares of the biopharmaceutical company’s stock valued at $721,000 after acquiring an additional 98 shares in the last quarter. Argentarii LLC grew its holdings in shares of Gilead Sciences by 3.0% in the first quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company’s stock valued at $380,000 after acquiring an additional 99 shares in the last quarter. Perkins Coie Trust Co grew its holdings in shares of Gilead Sciences by 2.6% in the first quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company’s stock valued at $435,000 after acquiring an additional 100 shares in the last quarter. Finally, Investment Research & Advisory Group Inc. lifted its stake in Gilead Sciences by 33.3% in the first quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 100 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Insider Transactions at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction on Monday, July 28th. The stock was sold at an average price of $113.94, for a total value of $1,139,400.00. Following the transaction, the chief executive officer owned 605,725 shares of the company’s stock, valued at $69,016,306.50. This represents a 1.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the transaction, the insider directly owned 114,168 shares in the company, valued at approximately $13,532,333.04. This represents a 19.70% decrease in their position. The disclosure for this sale can be found here. Insiders sold 82,000 shares of company stock worth $9,402,130 in the last three months. Insiders own 0.27% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on GILD shares. Royal Bank Of Canada upped their price objective on Gilead Sciences from $96.00 to $98.00 and gave the company a “sector perform” rating in a research note on Friday, August 8th. Daiwa Capital Markets upgraded Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price objective on the stock in a research note on Tuesday, August 19th. Truist Financial upgraded Gilead Sciences from a “hold” rating to a “buy” rating and upped their price objective for the company from $108.00 to $127.00 in a research note on Friday, August 8th. JPMorgan Chase & Co. upped their price objective on Gilead Sciences from $135.00 to $145.00 and gave the company an “overweight” rating in a research note on Tuesday, September 16th. Finally, Dbs Bank upgraded Gilead Sciences to a “moderate buy” rating in a research note on Friday, September 5th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and an average price target of $117.17.

Gilead Sciences Stock Up 1.9%

GILD opened at $112.69 on Friday. The stock has a market cap of $139.83 billion, a PE ratio of 22.45, a P/E/G ratio of 0.77 and a beta of 0.34. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 52 week low of $83.98 and a 52 week high of $121.83. The business’s fifty day simple moving average is $114.34 and its 200 day simple moving average is $109.94.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating analysts’ consensus estimates of $1.96 by $0.05. The business had revenue of $7.08 billion for the quarter, compared to analysts’ expectations of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm’s revenue was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s dividend payout ratio is currently 62.95%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.